
Sign up to save your podcasts
Or


In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.
Our Guest:
Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides, we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer.
Our Guests:
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Live From ASH, New Orleans:
In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans.
Our Guest:
Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Live From ASH, New Orleans:
In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
Our Guest:
Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada.
Our Guest:
Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer.
Our Guest:
Our guest for this episode is Dr. David Cescon, a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Ontario, where his clinical practice is devoted to the care of patients with breast cancer.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination.
Our Guest:
Our guest is Dr. Cowan, who is an Associate Scientist at The Ottawa Hospital Research Institute and Assistant Professor at The University of Ottawa. Dr. Cowan is also cross-appointed as an Assistant Professor at the Department of Biochemistry, Microbiology and Immunology and a Physician for the Division of Infectious Diseases at The Ottawa Hospital in Ontario. Her clinical and research focus is on prevention of infection in immunocompromised patients
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination.
Our Guest:
Our guest is Dr. Dimas Yusuf, Medical Oncologist and specialist in general internal medicine at Pacific Specialty Care in Delta, BC. He is also the Managing Director of OncoCare Health Incorporated in Vancouver, BC, which delivers cutting edge technologies and insights to advance cancer care.
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this second episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with hematological malignancies who are not able to mount a sufficient antibody response to vaccination.
Our Guest:
Our guest is Dr Laurie Sehn, Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia.
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Bienvenue dans la série de balados d’IMPACT Medicom sur la prophylaxie contre la COVID-19.
Notre invitée
Notre invitée dans l’épisode d’aujourd’hui est Annick Dufour, chef adjointe au département de pharmacie du CISSS Montérégie-Centre, au Québec au niveau des soins pharmaceutiques, de la recherche clinique et de l’oncologique. Elle est pharmacienne en oncologie depuis plusieurs années. Elle est également présidente du Comité d’évolution de la pratique des soins pharmaceutiques (CEPSP) du programme québécois de cancérologie du ministère de la Santé et des Services sociaux (MSSS)
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
From the publisher's feed
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic…

112,266 Listeners